In the HSGX longs community (i.e. Stocktwits) it is expected that there will be another update by the company CEO Adam Grizley by the end of year. As there haven't been any updates on the FDA discussions concerning BLA submission since 11-29-2018. The product NeoCart failed phase 3 because it didn't meet Histogenics criteria, not the FDA's. While the FDA continue to go over the data Histogenics stands by with a steady gain in SP. Go long, go strong, or go home. I'm in for the ride through 2019. Maybe compounding in the dips along the way. Gonna be a great ride!